Targeting a market that could reach $1.1 trillion by 2050, Cortexyme (CRTX) will probably interest institutional investors. Besides, the company appears to have sufficient equity financing to complete its Phase 2-3 clinical trial. In addition, the fact that Pfizer (PFE) is among the shareholders is also very appealing. The only issue is that the company expects to deliver top-line results in 2021. The market will have to wait for more than two years, which is a long time for some investors.
Source: Prospectus
Source: Prospectus
Business
Founded in 2012, Cortexyme is